Understanding NIH Impact Scores
As NIH review results are released, many applicants are asking the same question: how should I interpret my outcome, and what does it mean for funding? Recent NIH review cycles have introduced clearer distinctions in how applications are categorized, making it especially important to understand what your result actually signals.
How NIH Review Outcomes Are Assigned
NIH study sections now generally place applications into one of three categories during peer review:
1. Not Discussed
Applications in this category were not selected for full discussion by the study section. This typically means reviewers felt the application was not competitive relative to others in the pool.
No overall impact score is assigned
Written critiques are still provided
These applications are generally not considered for funding in the current cycle
While disappointing, this outcome can still provide useful feedback for a substantial revision or repositioning.
2. Not Discussed – Competitive
This is a newer and important distinction. These applications were not discussed, but reviewers considered them borderline or potentially competitive.
No overall impact score is assigned
Reviewer comments often indicate specific, fixable weaknesses
These applications may be close to discussion thresholds in strong review rounds
A “Not Discussed – Competitive” outcome often signals that a targeted resubmission could meaningfully improve funding chances.
3. Scored
Applications that are discussed by the study section receive an overall impact score, typically ranging from 10 (best) to 90.
Lower scores indicate stronger perceived impact
Being scored means the application cleared the initial competitiveness bar
A scored application can still fall inside or outside likely funding ranges, depending on institute priorities and budget
From Impact Score to Funding Decision
Impact scores are evaluated in the context of institute-specific paylines or zones of consideration. A payline represents the approximate score threshold below which applications are more likely to be funded, based on available funds and application volume.
Applications scoring better than the payline are more likely to be funded
Applications just outside the payline may still be considered, especially with strong programmatic relevance
Applications well outside the payline typically require either exceptional justification or resubmission
It’s important to note that many NIH institutes do not publish formal paylines, particularly for SBIR and STTR programs.
What’s New in Current NIH Funding Cycles
Recent funding cycles have placed increased emphasis on:
Programmatic fit, not just numerical rank
Portfolio balance and strategic priorities
Institute-level discretion, particularly for small business awards
As a result, applicants with competitive scores near traditional paylines are seeing more variability in outcomes. Early communication with Program Officers (POs) has become increasingly valuable, especially for applications that are scored or labeled “Not Discussed – Competitive.”
SBIR and STTR Applications: Additional Context
For SBIR (R43/R44) and STTR (R41/R42) applications, funding decisions depend on more than the impact score alone. Reviewers and institutes also weigh:
Commercial and translational potential
Technical feasibility and risk
Alignment with institute-specific missions
Because SBIR/STTR paylines are often unpublished, understanding how your review outcome is categorized is a key signal for next steps.
What to Do After You Receive Your Outcome
Once your NIH review results are released:
Identify whether your application was Not Discussed, Not Discussed–Competitive, or Scored
Carefully review reviewer comments for common themes
Compare your outcome to recent institute funding patterns
Consider outreach to your Program Officer to assess competitiveness and strategy
Decide whether revisions could materially improve your positioning
While no single outcome guarantees funding, understanding how NIH now categorizes applications allows you to make more informed, strategic decisions about resubmission and next steps.
If you’d like our team’s free assessment, click here.